Sanjit S. Jolly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sanjit S. Jolly has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Salim Yusuf
6 shared publications- Philippe Gabriel Steg
Université de Paris, Assistance Publique‐Hôpitaux de Paris, French Alliance for Cardiovascular Trials, INSERM U1148
4 shared publications Shamir R. Mehta
4 shared publications- Alvaro Avezum
Hospital Alemão Oswaldo Cruz
3 shared publications - Andrzej Budaj
Centre of Postgraduate Medical Education, Department of Cardiology, Grochowski Hospital, Warsaw, Poland
3 shared publications - Keith A. A. Fox
Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
3 shared publications
Latest Publications
- 1 August 2014
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 10 (T) , T35-T38
Aspiration thrombectomy in ST-elevation myocardial infarction
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 August 2014
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 10 (T) , T35-T38
Aspiration thrombectomy in ST-elevation myocardial infarction
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 August 2013
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 24 (5) , 412-418
Impact of access to hospitals with catheterization facilities in the second Gulf Registry of Acute Coronary Events (Gulf RACE-2)
It is currently unclear whether acute coronary syndrome patients who access hospitals with catheterization facilities, with or without an on-site percutaneous coronary intervention (PCI), have better outcomes in real-life clinical practice. This 9-month prospective study was carried out in six Arabian Gulf countries. Patients in hospitals with catheterization facilities [20/65 hospitals; 3615/6847 (52.8%) patients] were more likely to show evidence of cardiovascular risk factors (P<0.001) and more likely to undergo revascularization procedures that were mostly performed (≥80%) in low-risk and intermediate-risk patients. Patients in these centres experienced significantly higher rates of medical therapies and shorter door-to-needle times [median (IQR): 33 (40) vs. 43.5 (43) min, P<0.001]; 14.1% had primary PCI. They also had less in-hospital recurrent ischaemia, recurrent myocardial infarction, congestive heart failure and stroke, but more cardiogenic shock and major bleeding, and they had similar adjusted mortality rates in-hospital [odds ratio (OR): 1.06, 95% confidence interval (CI): 0.88-1.27] and at 30-day (OR: 1.11, 95% CI: 0.91-1.36) and 1-year (OR: 1.06, 95% CI: 0.89-1.27) follow-ups. Access to hospitals with catheterization facilities, with or without on-site PCI, was associated with a reduction in recurrent myocardial infarction and recurrent ischaemia, but not mortality. Further efforts are required to target revascularization procedures for higher risk patients as well as to widely implement primary PCI programmes.
- 1 August 2013
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 24 (5) , 412-418
Impact of access to hospitals with catheterization facilities in the second Gulf Registry of Acute Coronary Events (Gulf RACE-2)
It is currently unclear whether acute coronary syndrome patients who access hospitals with catheterization facilities, with or without an on-site percutaneous coronary intervention (PCI), have better outcomes in real-life clinical practice. This 9-month prospective study was carried out in six Arabian Gulf countries. Patients in hospitals with catheterization facilities [20/65 hospitals; 3615/6847 (52.8%) patients] were more likely to show evidence of cardiovascular risk factors (P<0.001) and more likely to undergo revascularization procedures that were mostly performed (≥80%) in low-risk and intermediate-risk patients. Patients in these centres experienced significantly higher rates of medical therapies and shorter door-to-needle times [median (IQR): 33 (40) vs. 43.5 (43) min, P<0.001]; 14.1% had primary PCI. They also had less in-hospital recurrent ischaemia, recurrent myocardial infarction, congestive heart failure and stroke, but more cardiogenic shock and major bleeding, and they had similar adjusted mortality rates in-hospital [odds ratio (OR): 1.06, 95% confidence interval (CI): 0.88-1.27] and at 30-day (OR: 1.11, 95% CI: 0.91-1.36) and 1-year (OR: 1.06, 95% CI: 0.89-1.27) follow-ups. Access to hospitals with catheterization facilities, with or without on-site PCI, was associated with a reduction in recurrent myocardial infarction and recurrent ischaemia, but not mortality. Further efforts are required to target revascularization procedures for higher risk patients as well as to widely implement primary PCI programmes.
- 1 February 2011
- Published by Elsevier in American Heart Journal
- Vol. 161 (2) , 254-260.e4
Design and rationale of the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes
- 1 February 2011
- Published by Elsevier in American Heart Journal
- Vol. 161 (2) , 254-260.e4
Design and rationale of the RadIal Vs. femorAL access for coronary intervention (RIVAL) trial: A randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromes
Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events
Background The objective of this study was to determine if the extent of quantitative troponin elevation predicted mortality as well as in-hospital complications of cardiac arrest, new heart failure and cardiogenic shock. Design 16 318 patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) from the Global Registry of Acute Coronary Events (GRACE) were included. The maximum 24 h troponin value as a multiple of the local laboratory upper limit of normal was used. The population was divided into five groups based on the degree of troponin elevation, and outcomes were compared. An adjusted analysis was performed using quantitative troponin as a continuous variable with adjustment for known prognostic variables. Results For each approximate 10-fold increase in the troponin ratio, there was an associated increase in cardiac arrest, sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) (1.0, 2.4, 3.4, 5.9 and 13.4%; pConclusion The extent of troponin elevation is an independent predictor of morbidity and mortality.
Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events
Background The objective of this study was to determine if the extent of quantitative troponin elevation predicted mortality as well as in-hospital complications of cardiac arrest, new heart failure and cardiogenic shock. Design 16 318 patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) from the Global Registry of Acute Coronary Events (GRACE) were included. The maximum 24 h troponin value as a multiple of the local laboratory upper limit of normal was used. The population was divided into five groups based on the degree of troponin elevation, and outcomes were compared. An adjusted analysis was performed using quantitative troponin as a continuous variable with adjustment for known prognostic variables. Results For each approximate 10-fold increase in the troponin ratio, there was an associated increase in cardiac arrest, sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) (1.0, 2.4, 3.4, 5.9 and 13.4%; pConclusion The extent of troponin elevation is an independent predictor of morbidity and mortality.
- Open Access
- 30 August 2010
- Published by American Medical Association (AMA) in JAMA
- Vol. 304 (12) , 1339-1349
Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial
In recent years, important advances have been made in the management of non–ST-segment elevation acute coronary syndromes, with new antithrombotic agents, increasing use of percutaneous coronary intervention (PCI) for high-risk cases, and improved secondary prevention. Among newer antithrombotics, fondaparinux, a synthetic factor Xa inhibitor, has recently emerged as an attractive option. Fondaparinux was compared with subcutaneous enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS-5) trial, a large international randomized trial.1 ST elevation acute coronary syndrome was evaluated in the OASIS-6 trial.2 In OASIS-5, fondaparinux was noninferior to enoxaparin for the primary efficacy outcome of death, myocardial infarction (MI), and refractory ischemia but halved major bleeding leading to a significant mortality reduction with fondaparinux compared with enoxaparin. However, in OASIS-5, there was a small but significant increase in catheter-related thromboses with fondaparinux in patients who underwent cardiac catheterization or PCI. This result prompted the OASIS investigators and guideline committees to recommend the use of unfractionated heparin as adjunctive therapy at the time of PCI for patients with non-ST-segment elevation acute coronary syndromes who were treated with fondaparinux and undergoing PCI3-5; although the range of dosing recommended differs between the European Society of Cardiology guidelines (50-100 U/kg) and American College of Cardiology–American Heart Association guidelines (50-60 U/kg irrespective of glycoprotein IIb/IIIa [GpIIb-IIIa] use), reflecting uncertainty because the dosing is based on analysis of limited retrospective data.
- 30 August 2010
- Published by American Medical Association (AMA) in JAMA
- Vol. 304 (12) , 1339-1349
Open AccessLow-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial
In recent years, important advances have been made in the management of non–ST-segment elevation acute coronary syndromes, with new antithrombotic agents, increasing use of percutaneous coronary intervention (PCI) for high-risk cases, and improved secondary prevention. Among newer antithrombotics, fondaparinux, a synthetic factor Xa inhibitor, has recently emerged as an attractive option. Fondaparinux was compared with subcutaneous enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS-5) trial, a large international randomized trial.1 ST elevation acute coronary syndrome was evaluated in the OASIS-6 trial.2 In OASIS-5, fondaparinux was noninferior to enoxaparin for the primary efficacy outcome of death, myocardial infarction (MI), and refractory ischemia but halved major bleeding leading to a significant mortality reduction with fondaparinux compared with enoxaparin. However, in OASIS-5, there was a small but significant increase in catheter-related thromboses with fondaparinux in patients who underwent cardiac catheterization or PCI. This result prompted the OASIS investigators and guideline committees to recommend the use of unfractionated heparin as adjunctive therapy at the time of PCI for patients with non-ST-segment elevation acute coronary syndromes who were treated with fondaparinux and undergoing PCI3-5; although the range of dosing recommended differs between the European Society of Cardiology guidelines (50-100 U/kg) and American College of Cardiology–American Heart Association guidelines (50-60 U/kg irrespective of glycoprotein IIb/IIIa [GpIIb-IIIa] use), reflecting uncertainty because the dosing is based on analysis of limited retrospective data.
- Open Access
- 9 February 2010
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 31 (5) , 522-524
Which antithrombotic to use during PCI?
With >2 million percutaneous coronary intervention (PCI) procedures performed worldwide annually, the optimal choice of antithrombotic therapy during PCI is of critical importance. There are three main choices for antithrombotic therapy during PCI: (i) heparin alone: (ii) heparin + glycoprotein (GP) IIb IIIa inhibitor; or (iii) bivalirudin.
- 9 February 2010
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 31 (5) , 522-524
Open AccessWhich antithrombotic to use during PCI?
With >2 million percutaneous coronary intervention (PCI) procedures performed worldwide annually, the optimal choice of antithrombotic therapy during PCI is of critical importance. There are three main choices for antithrombotic therapy during PCI: (i) heparin alone: (ii) heparin + glycoprotein (GP) IIb IIIa inhibitor; or (iii) bivalirudin.
- Top Cited Papers
- 1 January 2009
- Published by Elsevier in American Heart Journal
- Vol. 157 (1) , 132-140
Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: A systematic review and meta-analysis of randomized trials
- 1 January 2009
- Published by Elsevier in American Heart Journal
- Vol. 157 (1) , 132-140
Top Cited PapersRadial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: A systematic review and meta-analysis of randomized trials
- Open Access
- 26 September 2008
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (8) , 900-907
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study
In the setting of percutaneous coronary intervention (PCI), due to a paucity of data, the optimal dose of aspirin is uncertain. We evaluated the safety of different doses of aspirin after PCI. In the PCI-CURE study, 2658 patients with acute coronary syndromes undergoing PCI were stratified into three aspirin dose groups ≥200 mg (high, n = 1064), 101–199 mg (moderate, n = 538), and ≤100 mg (low, n = 1056). For efficacy, the moderate- (7.4%) and high-dose groups (8.6%) had similar rates of cardiovascular death, myocardial infarction, or stroke compared with the low-dose group (7.1%). For safety, major bleeding was increased with high-dose aspirin [3.9, 1.5, and 1.9% in the high-, moderate-, and low-dose groups; hazard ratio (HR) of high vs. low dose 2.05 (95% CI 1.20–3.50, P = 0.009]. The net adverse clinical events (death, MI, stroke, major bleeding) favoured low-over high-dose aspirin (8.4 vs. 11.0%, HR 1.31, 95% CI 1.00–1.73 P = 0.056). In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance.
- 26 September 2008
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (8) , 900-907
Open AccessEffects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study
In the setting of percutaneous coronary intervention (PCI), due to a paucity of data, the optimal dose of aspirin is uncertain. We evaluated the safety of different doses of aspirin after PCI. In the PCI-CURE study, 2658 patients with acute coronary syndromes undergoing PCI were stratified into three aspirin dose groups ≥200 mg (high, n = 1064), 101–199 mg (moderate, n = 538), and ≤100 mg (low, n = 1056). For efficacy, the moderate- (7.4%) and high-dose groups (8.6%) had similar rates of cardiovascular death, myocardial infarction, or stroke compared with the low-dose group (7.1%). For safety, major bleeding was increased with high-dose aspirin [3.9, 1.5, and 1.9% in the high-, moderate-, and low-dose groups; hazard ratio (HR) of high vs. low dose 2.05 (95% CI 1.20–3.50, P = 0.009]. The net adverse clinical events (death, MI, stroke, major bleeding) favoured low-over high-dose aspirin (8.4 vs. 11.0%, HR 1.31, 95% CI 1.00–1.73 P = 0.056). In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance.